Evidence map›Paper›PMID 41234598›Full record

ArticleTranslational lung cancer research2025

Evaluation of gefitinib alone or combined with bevacizumab in patients with

Xinmin Zhao, Xianghua Wu, Huijie Wang, Hui Yu, Si Sun, Zhihuang Hu, Ying Lin, Yao Zhang, Bo Yu, Zhenhua Wu and 6 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04425187 (Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC Clinical Study of L858R Positive Mutation Patients), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04425187 phase2unknown statusnot on this map

Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC Clinical Study of L858R Positive Mutation Patients

TypeinterventionalSponsorFudan UniversityRan2020 to 2022Enrolled120ConditionsPFSArmsGefitinib, Bevacizumab Combined With Gefitinib
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xinmin ZhaoDepartment of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xianghua WuDepartment of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Huijie WangDepartment of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Hui YuDepartment of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Si SunDepartment of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhihuang HuDepartment of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Ying LinDepartment of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yao ZhangDepartment of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Bo YuDepartment of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhenhua WuDepartment of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Kangli XiongGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
Cuicui LiuGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
Song WangGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
Hua BaoGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
Qiuxiang OuGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China.
Jialei WangDepartment of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with advanced non-small cell lung cancer (NSCLC) harboring Methods: In this randomized trial, 81 stage III/IV L858R-mutant NSCLC patients received gefitinib alone or gefitinib plus bevacizumab. The primary endpoint was progression-free survival (PFS), with secondary endpoints including objective response rate (ORR) and safety. Plasma ctDNA was evaluated for prognostic value and detection of treatment-related resistance. Results: Combination therapy significantly improved median PFS (15.1 Conclusions: Gefitinib plus bevacizumab shows promising efficacy and tolerability in Trial Registration: ClinicalTrials.gov NCT04425187.

Indexed as

bevacizumabEGFR L858R mutationgefitinibNon-small cell lung cancer (NSCLC)vascular endothelial growth factor (VEGF)

Identifiers

PMID41234598
PMCPMC12605247

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.